We are live on ! Find out more
VBIO

Valion Bio
VBIO

8 hedge funds and large institutions have $90.7K invested in Valion Bio in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more capital invested

Capital invested by funds: $69.8K → $90.7K (+$20.9K)

0% more funds holding

Funds holding: 8 → 8 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

1.7% less ownership

Funds ownership: 4.53% → 2.83% (-1.7%)

Holders
8
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$16K
2
GSC
Ground Swell Capital
South Carolina
+$10.6K
3
Two Sigma Investments
Two Sigma Investments
New York
+$3.37K
4
TRCT
Tower Research Capital (TRC)
New York
+$116

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$10.8K
2
TSS
Two Sigma Securities
New York
-$7.12K
3
VF
Virtu Financial
New York
-$5K
4
Renaissance Technologies
Renaissance Technologies
New York
-$4.39K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$3.93K

VBIO Hedge Fund Activity: Q4 2024 in Review

8 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q4 2024, worth a combined $90.7K — up 30% from $69.8K a quarter earlier.

Fund positioning in VBIO was balanced in Q4 2024: 4 funds opened new positions, 4 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was HRT Financial, opening a new position worth an estimated $16K. The largest seller was UBS Group, cutting an estimated $10.8K.

  • 8 institutional investors held Valion Bio (VBIO) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $90.7K of Valion Bio stock for Q4 2024, up 30% quarter-over-quarter.
  • 4 funds opened new Valion Bio positions in Q4 2024 and 4 closed out, a net change of 0 holders.
  • The largest Valion Bio buyer in Q4 2024 was HRT Financial, an estimated $16K added.
  • The largest Valion Bio seller in Q4 2024 was UBS Group, an estimated $10.8K sold.

Based on aggregated 13F filings for Q4 2024.